![](https://investorshub.advfn.com/uicon/280555.png?cb=1594066301)
Tuesday, October 25, 2022 5:22:27 AM
October 24 2022 - 07:30PM
PR Newswire (US)
Alert
Share On Facebook
- Taysha Gene Therapies is an emerging leader in the development of AAV gene therapies; new collaboration aimed at enhancing development of two of Taysha's novel product candidates for rare monogenic central nervous system diseases with serious unmet medical needs -
- Astellas to invest a total of $50 million to acquire 15% of the company and to receive an exclusive option to obtain an exclusive license for TSHA-102 for Rett syndrome and TSHA-120 for giant axonal neuropathy (GAN) -
- Astellas to receive certain rights related to any potential change of control of Taysha -
- Astellas to receive one Board observer seat on the Taysha Board of Directors -
TOKYO and DALLAS, Oct. 24, 2022 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and Taysha Gene Therapies, Inc. (NASDAQ: TSHA, CEO: RA Session II, "Taysha") today announced a strategic investment to support the advancement of Taysha's adeno-associated virus (AAV) gene therapy development programs for the treatment of Rett syndrome and GAN. The future options to potentially apply Astellas' global R&D, manufacturing and commercialization capabilities in gene therapy to Taysha's innovative AAV gene therapy development programs for genetic diseases of the central nervous system (CNS) create the opportunity for the two companies to enhance the development of novel treatment options for patients with Rett syndrome and GAN, who have serious unmet medical needs.
Astellas is excited to announce a new strategic investment to support development of Taysha Gene Therapies, Inc.’s AAV-based gene therapy programs.
Under the terms of the agreement, Astellas will invest a total of $50 million to acquire 15% of the outstanding common stock of Taysha and to receive an exclusive option to license two of Taysha's clinical stage programs: TSHA-102 for Rett syndrome and TSHA-120 for GAN. In addition, Taysha has granted Astellas certain rights related to any potential change of control of Taysha. Definitive agreements would be executed upon Astellas' exercise of any such option, and any change of control transaction would require approval by Taysha's stockholders.
Taysha is engaged in the development of intrathecally-delivered AAV gene therapies for monogenic CNS diseases. As a part of this platform approach, Taysha has a promising pipeline, including TSHA-102, which is the first-and-only gene therapy in clinical development for Rett syndrome, and TSHA-120, which is in Phase 1/2 development for the treatment of GAN and awaiting regulatory feedback.
Astellas is continuing to build its capability to bring novel gene therapies to patients, following the acquisition of Audentes (now Astellas Gene Therapies, California) in January 2020 and the construction of a state-of-the-art commercial GMP manufacturing facility in North Carolina, which was opened in June of this year.
"Gene therapy is the corner stone of Astellas' Primary Focus, Genetic Regulation*1; our goal is to bring new transformative treatment options to patients living with serious genetic diseases and limited treatment options," said Naoki Okamura, Chief Strategy Officer, at Astellas. "Taysha is an industry leader in CNS gene therapies and this partnership fits strategically with our long-term vision of expanding Astellas' gene therapy capabilities, allowing the company to impact the lives of a broader range of patients with urgent unmet medical needs."
"We are excited to enter this strategic investment with Astellas, a premier biopharmaceutical company with global R&D, manufacturing and commercial capabilities," said RA Session II, Taysha's Chief Executive Officer. "We believe this investment not only further validates the potential of our technology platform, but also reinforces the therapeutic and market opportunity of our two lead clinical assets."
To further strategically align Astellas and Taysha, in connection with its equity investment, Astellas will receive one Board observer seat on Taysha's Board of Directors, enabling Taysha to leverage Astellas' gene therapy clinical and commercial expertise as Taysha advances TSHA-120 and TSHA-102.
*1: Astellas has established a Focus Area Approach for its research and development strategy. For more information, please visit our website at https://www.astellas.com/en/science/focus-area-approach.
About TSHA-102
TSHA-102 is a self-complementary intrathecally delivered AAV9 gene replacement therapy under development for the treatment of Rett syndrome. TSHA-102 utilizes the novel miRNA-Responsive Auto-Regulatory Element (miRARE) platform to regulate transgene expression genotypically on a cell-by-cell basis. The miRARE technology is designed to prevent toxicity associated with transgene overexpression and can be potentially utilized across other indications. TSHA-102 has received Orphan Drug and Rare Pediatric Disease designations from the U.S. Food and Drug Administration (FDA) and Orphan Drug Designation from the European Commission.
About Rett Syndrome
Rett syndrome is a severe genetic neurodevelopmental disorder caused by a mutation in the X-linked MECP2 gene essential for neuronal and synaptic function in the brain. Primarily occurring in females, Rett syndrome is one of the most common genetic causes of severe intellectual disability worldwide. Patients have normal early development, with symptom onset typically beginning between 6 to 18 months of age. Rett syndrome is characterized by rapid developmental regression that leads to intellectual disabilities, loss of speech, loss of purposeful use of hands, loss of mobility, seizures, cardiac impairments and breathing issues. Currently, there are no approved therapies that treat the underlying cause of
Recent TSHA News
- Taysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants • GlobeNewswire Inc. • 06/26/2024 01:14:46 PM
- Taysha Gene Therapies Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants • GlobeNewswire Inc. • 06/25/2024 10:34:46 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/18/2024 11:45:05 AM
- Taysha Gene Therapies Announces Positive Clinical Data Across Adult and Pediatric Patients from Low Dose Cohort in Ongoing REVEAL Phase 1/2 Trials Evaluating TSHA-102 in Rett Syndrome • GlobeNewswire Inc. • 06/18/2024 11:30:00 AM
- Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 06/07/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/31/2024 08:18:23 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/30/2024 08:02:02 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/14/2024 08:18:01 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/14/2024 08:12:35 PM
- Taysha Gene Therapies Reports First Quarter 2024 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 05/14/2024 08:01:00 PM
- Taysha Gene Therapies to Release First Quarter 2024 Financial Results and Host Conference Call and Webcast on May 14 • GlobeNewswire Inc. • 05/07/2024 08:05:00 PM
- Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 05/03/2024 08:05:00 PM
- Taysha Gene Therapies Announces Regenerative Medicine Advanced Therapy (RMAT) Designation Granted by U.S. FDA for TSHA-102 in Rett Syndrome • GlobeNewswire Inc. • 05/02/2024 12:00:00 PM
- Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 04/05/2024 12:00:00 PM
- Another Biotech Steals The Show Following Major Clinical Data Release • AllPennyStocks.com • 03/20/2024 05:30:00 PM
- Taysha Gene Therapies Reports Full Year 2023 Financial Results and Provides Corporate and Clinical Updates • GlobeNewswire Inc. • 03/19/2024 08:01:00 PM
- US Index Futures Decline Ahead of Federal Reserve Meeting, Oil Prices Retreat • IH Market News • 03/19/2024 11:27:29 AM
- Taysha Gene Therapies to Release Full-Year 2023 Financial Results, Provide Corporate and Clinical Updates and Host Conference Call on March 19 • GlobeNewswire Inc. • 03/14/2024 08:26:51 PM
- Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 03/01/2024 10:08:33 PM
- Taysha Gene Therapies Announces Updates to TSHA-102 Clinical Program in Rett Syndrome • GlobeNewswire Inc. • 02/29/2024 01:00:00 PM
- Taysha Gene Therapies Provides Update on Deprioritized Pipeline Programs • GlobeNewswire Inc. • 02/15/2024 09:01:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/09/2024 09:24:55 PM
- Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 02/02/2024 01:00:00 PM
- Taysha Gene Therapies Announces Poster Presentation on TSHA-102 in Rett Syndrome at Upcoming British Paediatric Neurology Association 2024 Annual Conference • GlobeNewswire Inc. • 01/22/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/10/2024 01:06:30 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM
Branded Legacy, Inc. and Hemp Emu Announce Strategic Partnership to Enhance CBD Product Manufacturing • BLEG • Jun 27, 2024 8:30 AM
POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • POET • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM